Breaking News, Financial News

Financial Report: Elan

Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan 4Q Revenues: $269.8 million (+24%)        4Q Earnings: $169.5 million (loss of $83.5 million in 4Q07)     FY Revenues: $1.0 billion (+32%) FY Loss: $71.0 million (loss of $405 million FY08) Comments: Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition. For the quarter and full year, recorded Tysabri sales were $152.2 million ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters